Ashley House, APRN
Adult Health · Jonesboro, ARNPI 1679949457
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 25.7% of the total. Reporting peaked in 2023 at $722 and has fallen 51.2% since, to $353 in 2025.
Across 102 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$492
- Bayer$371
- GSK$163
- AstraZeneca$151
- Otsuka America Pharmaceutical, Inc.$143
- Novo Nordisk$109
- plus $483 from 19 others
What the payments were for
- Food & beverage$1,89899%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $492 |
| Bayer | 18 | $371 |
| GSK | 11 | $163 |
| AstraZeneca | 5 | $151 |
| Otsuka America Pharmaceutical, Inc. | 6 | $143 |
| Novo Nordisk | 2 | $109 |
| Esperion Therapeutics, Inc. | 1 | $74 |
| Lilly USA, LLC | 4 | $60 |
| Medtronic | 1 | $51 |
| Astellas Pharma US Inc | 3 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $27 |
| Pfizer | 2 | $27 |
| Novartis | 1 | $24 |
| Insmed, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Cvrx, Inc. | 1 | $17 |
| Hollister Incorporated | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Amgen | 1 | $14 |
| Merck | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Nevro Corp. | 1 | $12 |
| Vifor Pharma, Inc. | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
How this compares
$1,912 in reported general payments places this provider in the 70th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 44 | $57,114 |
| OzempicSemaglutide | 24 | $32,383 |
| RexultiBrexpiprazole | 12 | $16,984 |
| EliquisApixaban | 25 | $16,565 |
| JardianceEmpagliflozin | 15 | $12,455 |
| LinzessLinaclotide | 16 | $12,326 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,884 |
| Midodrine Hcl | 18 | $1,548 |
| Pantoprazole Sodium | 110 | $1,384 |
| Potassium Chloride | 82 | $1,108 |
| Celecoxib | 11 | $1,066 |
| Duloxetine Hcl | 76 | $992 |
| ValacyclovirValacyclovir Hcl | 16 | $948 |
| Gabapentin | 72 | $813 |
| Memantine Hcl | 37 | $761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $60 | $57,11444 claims |
| Novo NordiskOzempic | $109 | $32,38324 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $143 | $16,98412 claims |
| PfizerEliquis | $27 | $16,56525 claims |
| AbbVieLinzess | $492 | $12,32616 claims |
| GSKTrelegy Ellipta | $163 | $9,88413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 154 adult health providers in Arkansas.
Other adult health in Jonesboro
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Angela PugsleyJonesboro$4K
- Billie Barnes-WillsJonesboro$4K
- Kyle MedlinJonesboro$4K
- Margaret CooperJonesboro$3K
- Jana WheatonJonesboro$3K
- Samuel HiserJonesboro$2K
- Sara KoppJonesboro$2K
- Carie WellsJonesboro$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.